ESMO 2025: Ones to watch

ESMO 2025: Ones to watch

Explore the headlines set to surface at ESMO 2025. ADCs make their move into early-stage disease Drugs like Enhertu and Padcev, already headline-makers in metastatic disease, are now making waves in early-stage settings. DESTINY-Breast05, DESTINY-Breast11, and...
Spotlight on BTK Inhibitors in MS

Spotlight on BTK Inhibitors in MS

In recent years, interest in BTK inhibitors (BTKi) for MS has surged, with hopes that they could offer a new way to tackle the underlying drivers of the disease. But the journey, so far, has been a rollercoaster, and the delayed FDA decision on tolebrutinib marks the...
The Power of Words: In sickness and in health

The Power of Words: In sickness and in health

Author: Sam Hope, CEO, Beyond Blue Why is it that some people will happily stick to collagen powders and herbal elixirs but skip life-saving medication? This puzzling question became the spark for our self-funded study. Watching my own mother consistently and...